Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Impact Factor 13.965
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Circulation Research

  • My alerts
  • Sign In
  • Join

  • Impact Factor 13.965
  • Facebook
  • Twitter
  • Home
  • About this Journal
    • Editorial Board
    • Meet the Editors
    • Editorial Manifesto
    • Impact Factor
    • Journal History
    • General Statistics
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • Circulation Research Profiles
    • Trainees & Young Investigators
    • Research Around the World
    • News & Views
    • The NHLBI Page
    • Viewpoints
    • Compendia
    • Reviews
    • Recent Review Series
    • Profiles in Cardiovascular Science
    • Leaders in Cardiovascular Science
    • Commentaries on Cutting Edge Science
    • AHA/BCVS Scientific Statements
    • Abstract Supplements
    • Circulation Research Classics
    • In This Issue Archive
    • Anthology of Images
  • Resources
    • Online Submission/Peer Review
    • Why Submit to Circulation Research
    • Instructions for Authors
    • → Article Types
    • → Manuscript Preparation
    • → Submission Tips
    • → Journal Policies
    • Circulation Research Awards
    • Image Gallery
    • Council on Basic Cardiovascular Sciences
    • Customer Service & Ordering Info
    • International Users
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Editorial

Sympathetic Control of VEGF Angiogenic Signaling

Dual Regulations by α2-Adrenoceptor Activation?

Yuichi Hattori, Seiji Yamamoto, Naoyuki Matsuda
Download PDF
https://doi.org/10.1161/CIRCRESAHA.107.161855
Circulation Research. 2007;101:642-644
Originally published September 27, 2007
Yuichi Hattori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Yamamoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoyuki Matsuda
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading
  • adrenergic receptors
  • angiogenesis
  • vascular endothelial growth factor
  • vascular endothelial growth factor receptors

See related article, pages 682–691

It is now accepted that vascular endothelial growth factor (VEGF), a dimeric 46-kDa heparin-binding glycoprotein, is one of the most important vasculogenic and angiogenic factors reported to date. VEGF acts as a potent and specific mitogen for vascular endothelial cells in vitro and possesses a signal sequence which allows it to be secreted.1 Furthermore, numerous studies in vivo have shown that expression of VEGF and its receptors is upregulated during angiogenesis under physiological and pathological processes, such as development of the embryo,2–4 estrous cycle,5 tumor growth,6,7 and wound healing.8 Thus, VEGF plays an important role in the formation of new vessels from existing ones and the microvascular remodeling which involves structural alterations—usually enlargement—of arterioles, capillaries, or venules, in inflammatory or neoplastic diseases.

Different mechanisms appear to participate in the regulation of VEGF mRNA expression. It is well known that low oxygen tension is a strong inducer of VEGF mRNA expression in a variety of cells.6,9 Besides hypoxia-sensitive elements, the VEGF promoter region contains potential binding sites for the transcription factors AP-1, AP-2, and SP-1.10 Consistent with this fact, cAMP analogues and phorbol esters have been shown to upregulate VEGF mRNA in rat aortic smooth muscle cells,11 NIH 3T3 cells,12 or ovarian bovine granulosa cells,13 suggesting that VEGF expression is controlled by protein kinase A (PKA)- and protein kinase C (PKC)-mediated signals. Very interestingly, norepinephrine has been demonstrated to increase VEGF expression in murine brown adipocytes.14–16 Stimulation of β-adrenoceptors with norepinephrine activates adenylate cyclase via Gs regulatory proteins, resulting in an increased production of the second messenger cAMP, which leads to activation of PKA. Indeed, norepinephrine-induced upregulation of VEGF expression has been proven to be exclusively dependent on a β-adrenoceptor–mediated increase in cAMP levels and PKA activity.16 In addition, this pathway may use a Src-dependent pathway that branches off from the Src-Erk1/2 signaling cascade (Figure).16 Although the norepinephrine effect on VEGF expression in brown adipocytes could be mimicked by the β3-adrenoceptor agonists BRL-37344 and CGP-12177,16 a recent report has demonstrated that the β2-adrenoceptor agonists zilpaterol and clenbuterol induce the release of VEGF by macrophages exposed to endotoxin in a concentration-dependent manner,17 and the other study has suggested that both β1- and β2-adrenoceptors may be involved in norepinephrine-induced VEGF production in ovarian cancer cell lines.18 These findings imply that all subtypes of β-adrenoceptors would mediate the increasing effect of norepinephrine on VEGF expression depending on cell types. However, it should be kept in mind that β-adrenergic stimulation of VEGF expression may not necessarily be of major significance in regulating physiological angiogenesis. On the other hand, involvement of α1-adrenoceptors and the signaling pathway PKC activation in norepinephrine-induced VEGF expression in brown adipocytes appears to be minimal,16 and, conversely, it has been reported that the α1-adrenoceptor antagonist prazosin triggers the augmented production of VEGF in mouse skeletal muscles through shear stress–dependent endothelial nitric oxide synthase activation.19

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Figure. Schematic depicts adrenergic signals for angiogenesis involving the VEGF system. See text for details. NE indicates norepinephrine; AC, adenylate cyclase; KDR, VEGF receptor-2.

In this issue of Circulation Research, Muthig et al demonstrate a critical role for α2B-adrenoceptors in VEGF-associated angiogenic regulation in the placenta via the suppression of expression of the VEGF receptor-1 (Flt-1) and its soluble splice variant (sFlt-1).20 The authors created mice with a targeted deletion in the gene encoding α2B-adrenoceptors which were lost during the embryonic period because of a defect in placenta vascular labyrinth formation. They found that deletion of the α2B-adrenoceptor gene resulted in upregulation of sFlt-1 in spongiotrophoblast cells with a vasculogenesis defect in the placenta labyrinth and that neutralization of sFlt-1 by a specific antibody completely prevented the vascular defect in α2B-deficient placentae during mouse embryonic development.

Mammalian placentation requires extensive angiogenesis to establish a suitable vascular network for the supply of oxygen and nutrients to the fetus. In tissues where blood vessel growth is occurring, the net angiogenic effect is controlled by the balance between angiogenic inducers and inhibitors. The angiogenic inhibitor sFlt-1 is highly expressed by normal cytotrophoblasts21 and further elevated in cytotrophoblasts from preeclamptic placentae.22 Thus, elevated expression of sFlt-1 in preeclampsia plays a major role in the pathogenesis of this serious disorder of human pregnancy. Although the mechanisms regulating the synthesis and secretion of sFlt-1 during pregnancy are largely unknown, quite recent studies have indicated that thrombin and angiotensin II may act as an enhancer of sFlt-1 expression during pregnancy.23,24 Furthermore, despite the fact that hypoxic conditions enhance expression of VEGF,6,9 increased sFlt-1 expression in the human placenta under low oxygen condition mediated by hypoxia inducible factor-1α has been demonstrated.25 The study by Muthig et al not only suggests a novel mechanism of regulation of angiogenesis by alternative splicing of sFlt-1 mRNA but has important implications for understanding the pathogenesis of preeclampsia.

α2-Adrenoceptors are essential presynaptic regulators of norepinephrine release from sympathetic nerves. Thus, presynaptic α2-adrenoceptors are linked to inhibition of norepinephrine release from the sympathetic nerve terminals.26 This would result in a reduction in norepinephrine-induced upregulation of VEGF expression via β-adrenoceptor activation. From the study by Muthig et al, conversely, α2-adrenoceptors may potentially lead to activation of VEGF-mediated angiogenesis by repressing sFlt-1 expression. Therefore, α2-adrenoceptors may modulate VEGF function and thus angiogenesis because of the opposite dual regulations (Figure). However, whether suppression of antiangiogenic sFlt-1 expression by α2B-adrenoceptors can operate in angiogenesis and vasculogenesis in the adult organism remains the subject of ongoing studies.

Acknowledgments

Sources of Funding

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science of Technology of Japan.

Disclosures

None.

Footnotes

  • The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

References

  1. ↵
    Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992; 13: 18–32.
    OpenUrlCrossRefPubMed
  2. ↵
    Millauer B, Wizigmann-Voos S, Shnürch H, Martinez R, Møller NPH, Risau W, Ullrich A. High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993; 72: 835–846.
    OpenUrlCrossRefPubMed
  3. ↵
    Peters KG, de Vries C, Williams LT. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A. 1993; 90: 8915–8919.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Jakeman LB, Armanini M, Phillips HS, Ferrara N. Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology. 1993; 133: 848–859.
    OpenUrlCrossRefPubMed
  5. ↵
    Shweiki D, Itin A, Neufeld G, Gitay-Goren H, Keshet E. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest. 1993; 91: 2235–2243.
    OpenUrlCrossRefPubMed
  6. ↵
    Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992; 359: 843–845.
    OpenUrlCrossRefPubMed
  7. ↵
    Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumor angiogenesis for in human gliomas in vivo. Nature. 1992; 359: 845–848.
    OpenUrlCrossRefPubMed
  8. ↵
    Brown LF, Yeo KT, Berse B, Yeo TK, Senger DR, Dvorak HF, van de Water L. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med. 1992; 176: 1375–1379.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Semenza GL, Agani F, Iyer N, Jiang BH, Leung S, Wiener C, Yu A. Hypoxia-inducible factor 1: from molecular biology to cardiopulmonary physiology. Chest. 1998; 114: 40–45.
    OpenUrlPubMed
  10. ↵
    Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 1991; 266: 11947–11954.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    Pueyo ME, Chen Y, D’Angelo G, Michel JB. Regulation of vascular endothelial growth factor expression by cAMP in rat aortic smooth muscle cells. Exp Cell Res. 1998; 238: 354–368.
    OpenUrlCrossRefPubMed
  12. ↵
    Grugel S, Finkenzeller G, Weindel K, Barleon B, Marmé D. Both v-Ha-Ras and v-Ras stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem. 1995; 270: 25915–25919.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Garrido C, Saule S, Gospodarowicz D. Transcriptional regulation of vascular endothelial growth factor gene expression in ovarian bovine granulosa cells. Growth Fact. 1993; 8: 109–117.
    OpenUrlCrossRef
  14. ↵
    Asano A, Morimatsu M, Nikami H, Yoshida T, Saito M. Adrenergic activation of vascular endothelial growth factor mRNA expression in rat brown adipose tissue: implication in cold-induced angiogenesis. Biochem J. 1997; 328: 179–183.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Tonello C, Giordano A, Cozzi V, Cinti S, Stock MJ, Carruba MO, Nisoli E. Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats. FEBS Lett. 1999; 442: 167–172.
    OpenUrlCrossRefPubMed
  16. ↵
    Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a β-adrenoceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem. 2000; 275: 13802–13811.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    Verhoeckx KCM, Doornbos RP, Witkamp RF, van der Greef J, Rodenburg RJT. Beta-adrenergic receptor agonists induce the release of granulocyte chemotactic protein-2, oncostatin M, and vascular endothelial growth factor from macrophages. Int Immunopharmacol. 2006; 6: 1–7.
    OpenUrlCrossRefPubMed
  18. ↵
    Lutendorf SK, Cole S, Costanzo E, Bradley S, Coffin J, Rainwater K, Ritchie JM, Yang M, Sood AK. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003; 9: 4514–4521.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Baum O, Da Silva-Azevedo L, Willerding G, Wöckel A, Planitzer G, Gossrau R, Pries AR, Zakrzewicz A. Endothelial NOS is main mediator for shear stress-dependent angiogenesis in skeletal muscle after prazosin administration. Am J Physiol Heart Circ Physiol. 2004; 287: H2300–H2308.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Muthig V, Gilsbach R, Haubold M, Philipp M, Ivacevic T, Gessler M, Hein L. Upregulation of soluble vascular endothelial growth factor receptor 1 contributes to angiogenesis defects in the placenta of α2B-adrenoceptor-deficinet mice. Circ Res. 2007; 101: 682–691.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Clark DE, Smith SK, He Y, Day KA, Licence DR, Corps AN, Lammoglia R, Charnock-Jones DS. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Bio Reprod. 1998; 59: 1540–1548.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    Zhou Y, McMaster M, Woo K, Janatpour M, Perry J, Karpanen T, Alitalo K, Damsky C, Fisher SJ. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclamsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol. 2002; 160: 1405–1423.
    OpenUrlCrossRefPubMed
  23. ↵
    Lockwood CJ, Toti P, Arcuri F, Norwitz E, Funai EF, Huang S-TJ, Buchwalder LF, Krikun G, Schatz F. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua. Implication for preeclampsia. Am J Pathol. 2007; 170: 1398–1405.
    OpenUrlCrossRefPubMed
  24. ↵
    Zhou CC, Ahmad S, Mi T, Xia L, Abbasi S, Hewett PW, Sun C, Ahmed A, Kellems RE, Xia Y. Angiotensin II induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res. 2007; 100: 88–95.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    Nevo O, Soleymanlou N, Wu Y, Xu J, Kingdom J, Many A, Zamudio S, Caniggia I. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R1085–R1093.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    Starke K. Presynaptic α-autoreceptors. Rev Physiol Biochem Pharmacol. 1987; 107: 74–106.
    OpenUrl
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Circulation Research
September 28, 2007, Volume 101, Issue 7
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics

Article Tools

  • Print
  • Citation Tools
    Sympathetic Control of VEGF Angiogenic Signaling
    Yuichi Hattori, Seiji Yamamoto and Naoyuki Matsuda
    Circulation Research. 2007;101:642-644, originally published September 27, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.161855

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Circulation Research.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Sympathetic Control of VEGF Angiogenic Signaling
    (Your Name) has sent you a message from Circulation Research
    (Your Name) thought you would like to see the Circulation Research web site.
  • Share on Social Media
    Sympathetic Control of VEGF Angiogenic Signaling
    Yuichi Hattori, Seiji Yamamoto and Naoyuki Matsuda
    Circulation Research. 2007;101:642-644, originally published September 27, 2007
    https://doi.org/10.1161/CIRCRESAHA.107.161855
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Circulation Research

  • About Circulation Research
  • Editorial Board
  • Instructions for Authors
  • Abstract Supplements
  • AHA Statements and Guidelines
  • Permissions
  • Reprints
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
3355 Keswick Rd
Main Bldg 103
Baltimore, MD 21211
CircRes@circresearch.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured